- Published at
- by marketscreener.com
mixed
mixed
Bioasis Provides Corporate Update and Announces Suspension of Operations
NEW HAVEN, Conn., June 20, 2023 -- BIOASIS TECHNOLOGIES INC. , a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor... | June 20, 2023